Elanco Animal Health Incorporated [NYSE: ELAN] gained 6.76% on the last trading session, reaching $15.00 price per share at the time. The company report on September 8, 2022 that Elanco Announces Changes to its Board of Directors.
China Can't Stop US$0.25 Stock from Mining Ultra-Rare Metal
Here's one little-known company — trading undiscovered below 25-cents per share — that's advancing one of the largest and highest quality REE deposits in all of North America... and the Chinese can't do a damn thing about it! It's early stage... and that's excellent news for individual investors like you who have the foresight to act decisively on an emerging megatrend that's already being measured in the Tens of $Billions.
Simply click here and the name & trading symbol are yours.
Scott Ferguson stepping down from the Board.
Elanco Animal Health Incorporated represents 488.40 million in outstanding shares, while the company has a total market value of $6.66 billion with the latest information. ELAN stock price has been found in the range of $14.24 to $15.39.
If compared to the average trading volume of 5.85M shares, ELAN reached a trading volume of 12720941 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Elanco Animal Health Incorporated [ELAN]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ELAN shares is $21.25 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ELAN stock is a recommendation set at 2.60. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Morgan Stanley have made an estimate for Elanco Animal Health Incorporated shares, keeping their opinion on the stock as Equal-Weight, with their previous recommendation back on August 18, 2022. While these analysts kept the previous recommendation, JP Morgan dropped their target price from $28 to $24. The new note on the price target was released on August 16, 2022, representing the official price target for Elanco Animal Health Incorporated stock. Previously, the target price had yet another drop from $32 to $19, while Goldman kept a Sell rating on ELAN stock.
The Average True Range (ATR) for Elanco Animal Health Incorporated is set at 0.73, with the Price to Sales ratio for ELAN stock in the period of the last 12 months amounting to 1.43. The Price to Book ratio for the last quarter was 1.03, with the Price to Cash per share for the same quarter was set at 1.14. Price to Free Cash Flow for ELAN in the course of the last twelve months was 15.64 with Quick ratio for the last quarter at 1.50.
Trading performance analysis for ELAN stock
Elanco Animal Health Incorporated [ELAN] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -2.47. With this latest performance, ELAN shares dropped by -23.20% in over the last four-week period, additionally sinking by -43.14% over the last 6 months – not to mention a drop of -55.28% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ELAN stock in for the last two-week period is set at 33.67, with the RSI for the last a single of trading hit 37.31, and the three-weeks RSI is set at 33.00 for Elanco Animal Health Incorporated [ELAN]. The present Moving Average for the last 50 days of trading for this stock 18.59, while it was recorded at 14.77 for the last single week of trading, and 24.04 for the last 200 days.
Elanco Animal Health Incorporated [ELAN]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and Elanco Animal Health Incorporated [ELAN] shares currently have an operating margin of +6.34 and a Gross Margin at +43.55. Elanco Animal Health Incorporated’s Net Margin is presently recorded at -9.91.
Return on Equity for this stock declined to -5.89, with Return on Assets sitting at -2.76.
Elanco Animal Health Incorporated’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.50 and a Current Ratio set at 2.50.
Elanco Animal Health Incorporated [ELAN]: An earnings per share (EPS) analysis
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ELAN. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Elanco Animal Health Incorporated go to 13.00%.
An analysis of insider ownership at Elanco Animal Health Incorporated [ELAN]
There are presently around $7,044 million, in the hands of institutional investors. The top three institutional holders of ELAN stocks are: DODGE & COX with ownership of 49,206,190, which is approximately 72.124% of the company’s market cap and around 4.13% of the total institutional ownership; VANGUARD GROUP INC, holding 42,476,178 shares of the stock with an approximate value of $637.14 million in ELAN stocks shares; and PRIMECAP MANAGEMENT CO/CA/, currently with $458.27 million in ELAN stock with ownership of nearly -0.756% of the company’s market capitalization.
Positions in Elanco Animal Health Incorporated stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 223 institutional holders increased their position in Elanco Animal Health Incorporated [NYSE:ELAN] by around 47,873,912 shares. Additionally, 236 investors decreased positions by around 51,417,219 shares, while 68 investors held positions by with 370,309,985 shares. The mentioned changes placed institutional holdings at 469,601,116 shares, according to the latest SEC report filing. ELAN stock had 58 new institutional investments in for a total of 3,668,355 shares, while 84 institutional investors sold positions of 10,166,995 shares during the same period.